May/June 2026

Anti-VEGF Step Therapy: An Update

Despite ongoing advocacy efforts, this payer policy persists, putting vision at risk.

Lucas McGuire, BS; Baseer Ahmad, MD; and Jennifer Adeghate, MD

Angiogenesis 2026: Highlights

New data on wet and dry AMD therapies, AI, and more.

Alex Brodin, MA, Senior Editor, and Rebecca Hepp, MA, Editor-in-Chief

Landmark Trials in AMD

A summary of the clinical trials that have shaped—and continue to shape—how we treat AMD.

Saghar Bagheri, MD, PHD; Alberto Quarta, MD; Rouzbeh Abbasgholizadeh, MD; Alessandro Feo, MD; Paolo Forte, MD; David Sarraf, MD; Michael S. Ip, MD; and SriniVas R. Sadda, MD, FARVO

Starting Retina Fellowship: Four Strategies for Success

Make the most of this pivotal time in your retina career.

Justin C. Muste, MD, and David Fell, MD

Drug Interactions in Immunosuppressive Therapy for Uveitis

A review of the toxic relationships to avoid when managing patients with uveitis.

Ioannis Papasavvas, MD, and Carl P. Herbort, Jr, MD, PD

Ophthalmic Oncology Perspectives at ARDS

During the 54th annual meeting, Tara A. McCannel, MD, PhD, explored the utility of prognostic biopsy and the psychological ups and downs that come with a cancer diagnosis.

James Winebrake, MD

Pearls and Pitfalls of Treating GA and Wet AMD

Concurrent therapy can pose clinical challenges. Here’s how you can manage these patients and maximize outcomes.

Sean D. Adrean, MD, FAAO, and Wesley Han, BS